242 related articles for article (PubMed ID: 29105524)
1. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review.
Mancini I; Rotilio A; Coati I; Seracchioli R; Martelli V; Meriggiola MC
Gynecol Endocrinol; 2018 Jun; 34(6):456-459. PubMed ID: 29105524
[TBL] [Abstract][Full Text] [Related]
2. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy.
Gazzeri R; Galarza M; Gazzeri G
N Engl J Med; 2007 Dec; 357(23):2411-2. PubMed ID: 18057351
[No Abstract] [Full Text] [Related]
3. Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual.
Bergoglio MT; Gómez-Balaguer M; Almonacid Folch E; Hurtado Murillo F; Hernández-Mijares A
Endocrinol Nutr; 2013 May; 60(5):264-7. PubMed ID: 23022362
[TBL] [Abstract][Full Text] [Related]
4. Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient.
Cebula H; Pham TQ; Boyer P; Froelich S
Acta Neurochir (Wien); 2010 Nov; 152(11):1955-6. PubMed ID: 20811919
[No Abstract] [Full Text] [Related]
5. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.
Lee KS; Zhang JJY; Kirollos R; Santarius T; Nga VDW; Yeo TT
Sci Rep; 2022 Feb; 12(1):1942. PubMed ID: 35121790
[TBL] [Abstract][Full Text] [Related]
6. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.
Toorians AW; Thomassen MC; Zweegman S; Magdeleyns EJ; Tans G; Gooren LJ; Rosing J
J Clin Endocrinol Metab; 2003 Dec; 88(12):5723-9. PubMed ID: 14671159
[TBL] [Abstract][Full Text] [Related]
7. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study.
Weill A; Nguyen P; Labidi M; Cadier B; Passeri T; Duranteau L; Bernat AL; Yoldjian I; Fontanel S; Froelich S; Coste J
BMJ; 2021 Feb; 372():n37. PubMed ID: 33536184
[TBL] [Abstract][Full Text] [Related]
8. Gender-affirming hormone therapy associated with multiple meningiomas and atypical histology in a transgender woman.
Millward CP; Phillips E; Alalade AF; Gilkes CE
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34261631
[TBL] [Abstract][Full Text] [Related]
9. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
Asscheman H; Giltay EJ; Megens JA; de Ronde WP; van Trotsenburg MA; Gooren LJ
Eur J Endocrinol; 2011 Apr; 164(4):635-42. PubMed ID: 21266549
[TBL] [Abstract][Full Text] [Related]
10. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women.
Fung R; Hellstern-Layefsky M; Tastenhoye C; Lega I; Steele L
J Sex Med; 2016 Nov; 13(11):1765-1772. PubMed ID: 27693265
[TBL] [Abstract][Full Text] [Related]
11. [Cyproterone acetate and meningioma: The latest findings].
Schmutz JL
Ann Dermatol Venereol; 2018 May; 145(5):390-391. PubMed ID: 29703641
[No Abstract] [Full Text] [Related]
12. Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual.
García-Malpartida K; Martín-Gorgojo A; Rocha M; Gómez-Balaguer M; Hernández-Mijares A
Fertil Steril; 2010 Aug; 94(3):1097.e13-5. PubMed ID: 20227072
[TBL] [Abstract][Full Text] [Related]
13. A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen.
Gava G; Mancini I; Alvisi S; Seracchioli R; Meriggiola MC
Eur J Endocrinol; 2020 Dec; 183(6):561-569. PubMed ID: 33055297
[TBL] [Abstract][Full Text] [Related]
14. Probable Drug-Related Meningioma Detected During the Course of Medication Review Services.
Alderman CP
Consult Pharm; 2016 Sep; 31(9):500-4. PubMed ID: 27636874
[TBL] [Abstract][Full Text] [Related]
15. Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma.
Samarut E; Lugat A; Amelot A; Scharbarg E; Hadjadj S; Primot C; Loussouarn D; Thillays F; Buffenoir K; Cariou B; Drui D; Roualdes V
J Neurooncol; 2021 Mar; 152(1):115-123. PubMed ID: 33392938
[TBL] [Abstract][Full Text] [Related]
16. Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents.
Tack LJW; Heyse R; Craen M; Dhondt K; Bossche HV; Laridaen J; Cools M
J Sex Med; 2017 May; 14(5):747-757. PubMed ID: 28499525
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Venous Thromboembolism in Transgender Women Receiving Oral Estradiol.
Arnold JD; Sarkodie EP; Coleman ME; Goldstein DA
J Sex Med; 2016 Nov; 13(11):1773-1777. PubMed ID: 27671969
[TBL] [Abstract][Full Text] [Related]
18. Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy.
Deipolyi AR; Han SJ; Parsa AT
J Clin Neurosci; 2010 Oct; 17(10):1324-6. PubMed ID: 20594855
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.
Gooren LJ; Giltay EJ; Bunck MC
J Clin Endocrinol Metab; 2008 Jan; 93(1):19-25. PubMed ID: 17986639
[TBL] [Abstract][Full Text] [Related]
20. Cyproterone acetate and risk of meningioma: a nationwide cohort study.
Mikkelsen AP; Greiber IK; Scheller NM; Hilden M; Lidegaard Ø
J Neurol Neurosurg Psychiatry; 2022 Feb; 93(2):222-223. PubMed ID: 34187864
[No Abstract] [Full Text] [Related]
[Next] [New Search]
